GFI APAC announces the “2020 Asia Alt 100” Industry Disruptors in Alternative Protein

Significant opportunities identified in growing and processing raw materials in Asia The Good Food Institute Asia-Pacific (GFI APAC) today reveals the "2020 Asia Alt 100" organizations,...

Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal

SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and...

Avance Clinical在2020年生物科技創新組織數字會議上表示,TrialTrove數據顯示,澳大利亞開始復工

澳大利亞領先的生物科技合同研究組織Avance Clinical在今天的生物科技創新組織數字會議上宣布,目前,澳大利亞共有2413個計劃或在行測試項目。在澳大利亞,雖然新冠疫情肆虐,健康志願研究並未中止,只有27個一期或二期研究項目因各種原因暫停(TrialTrove,2020年6月9日)。 Avance Clinical高度讚揚澳大利亞工業界出色的新冠疫情管理能力,這就意味著,澳大利亞在維持臨床測試業務方面引領全球。 Avance Clinical首席戰略官Ben Edwards在2020年生物科技創新組織數字會議上介紹了澳大利亞臨床測試工作的諸多好處。 點擊下方鏈接,查看Avance Clinical生物科技創新組織數字會議演講稿。 https://www.bio.org/events/bio-digital/sessions/search?name=Avance%20Clinical Edwards先生講:“大約96%的工作支持中小型生物科技公司,執行一期和二期測試項目。我們的客戶遍及北美洲、加拿大、新西蘭、歐洲和亞洲。 澳大利亞在國際臨床測試方面具有無以倫比的優勢。我們對新冠疫情的管理是澳大利亞成為了臨床測試最佳目的地。 ” Avance Clinical是一家以靈活協作的方法聞名的中型全方位服務CRO,在管理早期試驗方面擁有20多年的經驗。 除了出色的新冠疫情管理能力,另一個重要因素就是速度、高質量場地和運營測試項目成本誘人。 - 澳大利亞政府對臨床試驗支出提供的43.5%以上的財政退款 - 臨床試驗無需IND,簡化監管流程 - 先進的醫療、研究和科學團體,領先的調查人員和KOL,以及現代化的醫療設施 觀看視頻-我們如何在新冠疫情肆虐的環境下開展工作。 https://tinyurl.com/yc2z6kjj 澳大利亞因其在FDA標準的科學合規性和研究卓越性、醫療保健先進性,以及有機會在臨床試驗競爭較少的環境中接觸患者等方面的優勢而享有盛譽聲譽,這也進一步增強了其作為臨床試驗目的地的優勢。 想了解更多關於在澳大利亞開展您下一項研究的優勢,請聯繫我們: https://www.avancecro.com/contact-us/ 關於 Avance Clinical Avance Clinical擁有20多年的從業經驗,目前是澳大利亞領先的合同研究機構之一。 Avance Clinical通過協調人員、技能和專業知識,促進高質量的藥物開發,以追求更健康的世界。 AvanceClinical憑藉其經驗豐富的團隊,致力於提供高質量的臨床研究服務。 Avance Clinical的知識和經驗庫也得益於精心挑選的專家在不斷地擴張,這些專家也表現出對所選領域的高度熱情。 Avance Clinical在成熟的臨床試驗生態系統中提供高質量的服務,包括世界級的研究人員和能夠訪問特定患者組群的中心。其他好處還包括: 1. 政府發放研發經費,意味著可享受超過43.5%的臨床試驗經費返利。 2. 遠程醫療在COVID-19大流行期間的樞紐作用——快速和連續性。 3. 網上問診(SIV)和研究的啟動在 5 —...

Avance Clinical在2020年生物科技创新组织数字会议上表示,TrialTrove数据显示,澳大利亚开始复工

澳大利亚领先的生物科技合同研究组织Avance Clinical在今天的生物科技创新组织数字会议上宣布,目前,澳大利亚共有2413个计划或在行测试项目。在澳大利亚,虽然新冠疫情肆虐,健康志愿研究并未中止,只有27个一期或二期研究项目因各种原因暂停(TrialTrove,2020年6月9日)。 Avance Clinical高度赞扬澳大利亚工业界出色的新冠疫情管理能力,这就意味着,澳大利亚在维持临床测试业务方面引领全球。 Avance Clinical首席战略官Ben Edwards在2020年生物科技创新组织数字会议上介绍了澳大利亚临床测试工作的诸多好处。 点击下方链接,查看Avance Clinical生物科技创新组织数字会议演讲稿。 https://www.bio.org/events/bio-digital/sessions/search?name=Avance%20Clinical Edwards先生讲:“大约96%的工作支持中小型生物科技公司,执行一期和二期测试项目。我们的客户遍及北美洲、加拿大、新西兰、欧洲和亚洲。 澳大利亚在国际临床测试方面具有无以伦比的优势。我们对新冠疫情的管理是澳大利亚成为了临床测试最佳目的地。” Avance Clinical是一家以灵活协作的方法闻名的中型全方位服务CRO,在管理早期试验方面拥有20多年的经验。 除了出色的新冠疫情管理能力,另一个重要因素就是速度、高质量场地和运营测试项目成本诱人。 - 澳大利亚政府对临床试验支出提供的43.5%以上的财政退款 - 临床试验无需IND,简化监管流程 - 先进的医疗、研究和科学团体,领先的调查人员和KOL,以及现代化的医疗设施 观看视频-我们如何在新冠疫情肆虐的环境下开展工作。https://tinyurl.com/yc2z6kjj 澳大利亚因其在FDA标准的科学合规性和研究卓越性、医疗保健先进性,以及有机会在临床试验竞争较少的环境中接触患者等方面的优势而享有盛誉声誉,这也进一步增强了其作为临床试验目的地的优势。 想了解更多关于在澳大利亚开展您下一项研究的优势,请联系我们: https://www.avancecro.com/contact-us/ 关于 Avance Clinical Avance Clinical拥有20多年的从业经验,目前是澳大利亚领先的合同研究机构之一。 Avance Clinical通过协调人员、技能和专业知识,促进高质量的药物开发,以追求更健康的世界。 AvanceClinical凭借其经验丰富的团队,致力于提供高质量的临床研究服务。Avance Clinical的知识和经验库也得益于精心挑选的专家在不断地扩张,这些专家也表现出对所选领域的高度热情。 Avance Clinical在成熟的临床试验生态系统中提供高质量的服务,包括世界级的研究人员和能够访问特定患者组群的中心。其他好处还包括: 1. 政府发放研发经费,意味着可享受超过43.5%的临床试验经费返利。 2. 远程医疗在COVID-19大流行期间的枢纽作用——快速和连续性。 3. 网上问诊(SIV)和研究的启动在 5 — 6周得以实现。 4. 临床试验不需要IND申报。 5....

SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress

Pipeline of Drug Candidates Has Vast Potential in the Future SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company...

TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital...

The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. Importantly in...

Joonghun Pharmaceutical of Korea Targets Overseas Markets for Coronavirus Diagnostic Kits

With the worldwide spread of the Novel Coronavirus (COVID-19), orders for Korean diagnostic kits continue to roll in. As part of the effort to...

Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies

CB6 demonstrated prophylactic and treatment effects in rhesus monkeys Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and...

Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by...

NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced...

Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed...

Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on...

Cyber Company to Supply 50M Health “COVI-PASS(TM)”

- Cyber tech company signs technology deal to supply 50M "COVI-PASS(TM)" Digital Health Passports to 15 countries - VST Enterprises signs deal with digital health...

Novotech COVID-19 Clinical Trial Clients Benefit from New Asia-Pacific Fast-Track Review Processes

SYDNEY - Asia-Pacific's largest specialist biotech CRO Novotech said many countries in the region were now fast-tracking their COVID-19 clients' clinical trials with expedited review...

Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a...

Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. HMM0112 is a Phase I trial conducted...

Impact Biomedical’s Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD...

SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with...

Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market

Prominent Advantages of Core Products Though the COVID-19 pandemic has blanketed the capital market in 2020, biotech stocks have stood out. Pharmaceutical stocks have become...

CStone announces acceptance of its first New Drug Application in mainland China by the...

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA)...

TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical...

TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK) is pleased to announce that the randomized Phase III clinical trial...

Path-Away(R), Active Ingredient in Plant-Based, Alcohol-Free NatShield(TM) Hand Sanitiser Developed by Holista CollTech, Tested...

Path-Away(R), a plant-based natural active ingredient used in the alcohol-free NatShield(TM) hand sanitiser developed by Malaysia-based and Australia-listed Holista CollTech (ASX: HCT), has been...

Skin Elements Enters Binding Agreement with Holista Colltech To Launch All Natural Skin-Friendly Sanitiser

Australian-listed companies Skin Elements Limited (ASX: SKN) ('Skin Elements') and Holista Colltech Limited (ASX:HCT) ('Holista') announced today a Binding Collaboration Term Sheet (Agreement) to...

Dyadic Announces Nonexclusive Research License with WuXi Biologics

Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform...